Clinical Trial Search

Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 1 participants

Primary: Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50% — 67.5; 67.2 PRI%

Primary: Percentage of Subjects With Drug-related Adverse Events. — 66.7; 55.6 Percentage of subjects

Primary: Change in Accuracy of the Belief That FDA Authorized COVID-19 Vaccines Are Safe and Effective — 20.1; 22.8; 24.2; 22.7 score on a 0-100 scale — p=0.998

Primary: Quality of Life as Measured by SF-36 — 42.77; 42.39; 43.77; 48.31 score on a scale — p=.48

Primary: Binocular Intermediate Vision — -0.02; 0.19 logMAR

Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 1; 2; 1; 3 Participants

Primary: Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting). — 61.39; 60.46; 79.94; 74.56 score on a scale — p=0.0113

Primary: Measure of Quality of Life Assessed by 14-item Center for Disease Control (CDC) Health Related Quality of Life Questioner — 9.11; 6.81 Days

Primary: Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge — 4.25; 4.89; 5.31 Percent change from resting diameter — p=.494

Primary: Apnea-Hypopnea Index — 11.5; 11.5; 18.8 events/hour — p=<0.0001

Primary: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE) — 57.1 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 3 Participants

Primary: Number of SLE Patients That Were Sampled for RNA-seq Differential Expression Analysis (Biological Replicates) — 20; 20; 20; 20 Participants